

GIORGIO SANTONI(male), (OP at UNICAM), E-mail: giorgio.santoni@unicam.it

Associate Professor in General Pathology, from 1992 and Full Professor in General Pathology from 2001 at the School of Pharmacy, University of Camerino, Camerino Italy. His research interest is focused on the role of TRP channels in cancer progression. He have recently participated in Research Projects financed with public funds at national level (PRIN 2017). He is author or co-author of more than 165 peer-reviewed publications, including reviews and book chapters, he possesses an H-index of 39 (Scopus, October 2019).

- 1986 General Pathology Speciality, University "La Sapienza", Rome, Italy.
- 1988 Research Associate at the Department of Microbiology and Immunology, College of Medicine, University of South Florida, Tampa, USA.
- 1991 Research Scholar at the Department of Microbiology and Immunology, College of Medicine, University of South Florida, Tampa, USA.
- 1994 Research Associate at the Moffitt Cancer Center & Research, Tampa, USA.
- PRIN 2010-13: Project Leader in Operative Unit of Camerino “ Le scienze omiche come strumento per la ricerca traslazionale in neurooncologia”.
- From 2014 Deputy Director of the School of Pharmacy, University of Camerino.
- 2014 Project Leader in a Project sponsored by Pfizer company: “Therapy of renal tumors”.
- AIRC 2014-2017: Project Leader of Operative Unit Camerino “Circulating tumor cells and exosomes in human pancreatic cancer. The impact on prognosis and treatment strategy” Project IG 2014 Id.15821.
- PRIN 2017: Project Leader of Operative Unit “Glial and neuronal plasticity in glioma: novel therapeutic targets”.
- 2019 Project Leader in a Project sponsored by Novartis company:“Effect of Ribociclib in HR+HER2- ABC.

Publications (Prof. Giorgio Santoni)

2020

1. **Santoni G**, Santoni M, Nabissi M, Marinelli O, Amantini C, Morelli MB. Emerging role of TRPML1 mucolipin endolysosomal channel in cancer. **J Cell Signal** **2020**, **1**, 4-7.
2. **Santoni G**, Amantini C, Nabissi M, Maggi F, Morelli MB. MicroRNA signature targeting Transient receptor potential channels in the prognosis and therapy of cancer. **J Cell Immunol** **2020**, **2**, 74-79.
3. **Santoni G**, Amantini C, Maggi F, Marinelli O, Santoni M, Nabissi M, Morelli MB. The TRPV2 cation channels: from urothelial cancer invasiveness to glioblastoma multiforme interactome signature. **Lab Invest.** **2020 Feb**;**100(2):186-198**. doi: [10.1038/s41374-019-0333-7](https://doi.org/10.1038/s41374-019-0333-7).
4. **Santoni G**, Morelli MB, Santoni M, Nabissi M, Marinelli O, Amantini C. Targeting Transient Receptor Potential Channels by MicroRNAs Drives Tumor Development and Progression. **Adv Exp Med Biol.** **2020**;**1131:605-623**. doi: [10.1007/978-3-030-12457-1_24](https://doi.org/10.1007/978-3-030-12457-1_24).
5. **Santoni G**, Morelli MB, Marinelli O, Nabissi M, Santoni M, Amantini C. Calcium Signaling and the Regulation of Chemosensitivity in Cancer Cells: Role of the Transient Receptor Potential Channels. **Adv Exp Med Biol.** **2020**;**1131:505-517**. doi: [10.1007/978-3-030-12457-1_20](https://doi.org/10.1007/978-3-030-12457-1_20).

6. **Santoni G**, Morelli MB, Amantini C, Nabissi M, Santoni M, Santoni A. Involvement of the TRPML Mucolipin Channels in Viral Infections and Anti-viral Innate Immune Responses. **Frontiers in Immunology, section Molecular Innate Immunity** **2020**, **11:739**.
7. Santoni G, Santoni M, Maggi F, Marinelli O, Maria Morelli MB. Emerging Role of Mucolipins TRPML channels in Cancer. *Frontiers in Oncology*. 2020, 10:659.
8. **Santoni G**, Maggi F, Amantini C, Marinelli O, Nabissi M, Morelli MB. Pathophysiological role of Transient Receptor Potential Mucolipin Channels in Oxidative Stress-induced Neurodegenerative diseases. **Frontiers in Physiology, section Membrane Physiology and Membrane Biophysics**. **2020. Mar 24, 11:251, doi.10.3389/fphys2020.00251**.
9. **Santoni G**, Morelli MB, Nabissi M, Maggi F, Marinelli O, Santoni M and Amantini C. Cross-talk between microRNA, Long non-coding RNAs and P21/CIP1 Cell Cycle Inhibitor signaling pathway in glioma and glioma stem cells: diagnostic, prognostic and therapeutic role. **J. Cancer Metastasis and Treatment** **2020; 6:22 DOI: 10.20517/2394-4722.2020.49**.
10. Marinelli O, Morelli MB, Annibali D, Tuyuarts S, Amantini C, Amant F, **Santoni G** and Nabissi M. The effects of cannabidiol and prognostic role of TRPV2 in human endometrial cancer. **Int J Mol Sci. 2020 Jul 29;21(15):5409. doi: 10.3390/ijms21155409**.
11. Luongo M, Marinelli O, Zeppa L, Aguzzi C, Morelli MB, Amantini C, Frassinetti A, di Costanzo M, Fanelli A, **Santoni G**, Nabissi M. Cannabidiol and oxygen-ozone combination induce cytotoxicity in human pancreatic adenocarcinoma cell lines. **Cancers (Basel). 2020 Sep 27;12(10):2774. doi: 10.3390/cancers12102774**.
12. Aguzzi C, Marinelli O, Zeppa L, **Santoni G**, Maggi F, Nabissi M. Evaluation of anti-inflammatory and immunoregulatory activities of Stimunex and Stimunex D3 in human monocytes/macrophages stimulated with LPS or IL4/IL13. **Biomed Pharmacother. 2020 Dec;132:110845. doi: 10.1016/j.biopha.2020.110845. Epub 2020 Oct 17**.
13. Torquati L., Tamburo S., Macusi A., Brunetti A., Iengo C., Sponsiello N., **Santoni G** and Nabissi M. Potential immunological effects of fermentable fibres in athletes. *PNS 79 (OCE2), E673, 2020*
14. Nabissi M, Marinelli O, Annibali D, Morelli MB, Zeppa L, Tuyuarts S, Aguzzi C, Amantini C, Maggi F, **Santoni G**, Amant F. Biological Function of PD-L2 and Correlation with Overall Survival in Type II Endometrial Cancer. **Front Oncol. 2020 Oct 28;10:538064. doi: 10.3389/fonc.2020.538064. eCollection 2020**.
15. **Santoni G**, Marinelli O, Maggi F, Nabissi M, Amantini C, Morelli MB, Santoni M, Battelli N. Exploring treatment with Ribociclib alone or in sequential/concurrent schedule with Everolimus in ER⁺HER2⁻ Rb wild-type and knock-down MCF-7 Breast Cancer cell line. **BMC Cancer. 2020 Nov 19;20(1):1119. doi: 10.1186/s12885-020-07619-1**.